Helene CE — Cross-Linked HA Dermal Filler with Lidocaine

Helene CE is a CE-certified Korean monophasic HA dermal filler — 24 mg/mL cross-linked hyaluronic acid + 0.3% lidocaine. Engineered for mid-to-deep dermal placement targeting nasolabial folds, lip augmentation, and moderate facial contouring. CE marking supports EU/international clinical use; sourced through licensed Korean aesthetic channel.

Helene CE Hyaluronic Acid Filler with Lidocaine is manufactured by Korean Aesthetic Manufacturer, a South Korea-based medical device and pharmaceutical company established in 2015. The product is part of the Helene dermal filler range, which is distributed across multiple international markets. Regulatory status: CE marked · KFDA registered · GMP certified.

Helene CE Hyaluronic Acid Filler with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Korean Aesthetic Manufacturer’s Monophasic HA Cross-Linking technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Korean Aesthetic Manufacturer’s clinical data, Helene CE Hyaluronic Acid Filler with Lidocaine delivers 9-12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Helene CE Hyaluronic Acid Filler with Lidocaine is engineered for mid to deep dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Helene CE Hyaluronic Acid Filler with Lidocaine regulatory status: CE marked · KFDA registered · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Helene CE Hyaluronic Acid Filler with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Helene CE Hyaluronic Acid Filler with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Helene CE Hyaluronic Acid Filler with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Helene CE shares the standard Korean HA filler profile — 24 mg/mL monophasic cross-linked HA with 0.3% premixed lidocaine — placing it in the same clinical category as Revolax Deep, Dermalax Deep Plus, and similar mid-density Korean fillers. Differentiation typically comes through manufacturer-specific cross-linking nuances, pricing positioning, and channel availability rather than dramatic clinical performance differences. Practitioners select among these comparable products based on supply continuity, training preferences, and patient-specific anatomical considerations.